All you need to know about biotech’s quest to CRISPR humans

How close are we to prescribing genome editing? Is all CRISPR created equal? And what does “exogenous” mean?

You can learn all of that by listening to STAT’s Sharon Begley and Adam Feuerstein, who hosted a webinar on the state of CRISPR when it comes to human therapy. They cover the pipelines of the three publicly traded CRISPR companies — Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics — and prepare you for what’s going to be a busy year in clinical trials.

They also delve into a pair of upstarts taking different approaches to genome editing: one with a technology all its own, and another making a bold bet on the future of genetic medicine.

Watch it here.